Brokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $10.29

Key Points

• Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received a consensus rating of "Buy" from nine analysts, with an average target price of $10.29 over the next year.
• The company's shares are currently trading at $5.67 and have recently seen a significant increase of 14.8%.
• Institutions own 32.45% of Aquestive Therapeutics, with several funds recently increasing their stakes in the company.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $10.2857.

AQST has been the topic of several analyst reports. Oppenheimer upped their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Monday, September 8th. Zacks Research upgraded Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Finally, Lifesci Capital upgraded Aquestive Therapeutics to a "strong-buy" rating in a report on Wednesday, September 3rd.

Aquestive Therapeutics Stock Down 8.8%

Shares of AQST stock traded down $0.50 on Monday, hitting $5.17. 4,551,042 shares of the stock were exchanged, compared to its average volume of 3,056,085. The business has a 50-day moving average of $4.26 and a 200 day moving average of $3.42. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $6.00.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Peter E. Boyd sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $5.30, for a total value of $79,500.00. Following the completion of the sale, the insider directly owned 288,323 shares of the company's stock, valued at $1,528,111.90. This trade represents a 4.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Cassie Jung sold 62,180 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $5.00, for a total value of $310,900.00. Following the completion of the sale, the chief operating officer directly owned 283,346 shares of the company's stock, valued at approximately $1,416,730. The trade was a 18.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 77,580 shares of company stock valued at $392,800. Insiders own 7.85% of the company's stock.

Institutional Trading of Aquestive Therapeutics

Hedge funds have recently made changes to their positions in the business. Summit Wealth & Retirement Planning Inc. acquired a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $29,000. Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $31,000. BNP Paribas Financial Markets lifted its position in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after buying an additional 4,134 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of Aquestive Therapeutics during the first quarter worth approximately $33,000. Finally, USAdvisors Wealth Management LLC acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $33,000. 32.45% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.